Technical Analysis for AGEN - Agenus Inc.

Grade Last Price % Change Price Change
grade A 3.67 -1.61% -0.06
AGEN closed down 1.61 percent on Friday, January 18, 2019, on 1.29 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical AGEN trend table...

Date Alert Name Type % Chg
Jan 18 Upper Bollinger Band Walk Strength 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 18 Upper Bollinger Band Touch Strength 0.00%
Jan 17 New Uptrend Bullish -1.61%
Jan 17 Expansion Breakout Bullish Swing Setup -1.61%
Jan 17 Pocket Pivot Bullish Swing Setup -1.61%
Jan 17 Volume Surge Other -1.61%
Jan 17 Wide Range Bar Range Expansion -1.61%
Jan 17 Parabolic Rise Strength -1.61%

Older signals for AGEN ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Agenus Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases. Its technology portfolio consists of saponin adjuvant based technologies and heat shock protein based technologies. The company offers Oncophage vaccine for the treatment of renal cell carcinoma in patients at intermediate risk of recurrence. Its products under development include QS-21 Stimulon adjuvant, which is in Phase III clinical trials for the treatment of malaria, melanoma, non-small cell lung cancer, and shingles, as well as for the treatment of various infectious diseases, multiple cancer types, and Alzheimer's disease; and HerpV, a therapeutic vaccine candidate that is in Phase 2 clinical trial for the treatment of genital herpes. The company's products under development also comprise Prophage series of cancer vaccines, including R-series candidates in RCC, M-series candidates in melanoma, and G-series candidates in glioma. Its Prophage series of cancer vaccines were tested in Phase III clinical trials for the treatment of renal cell carcinoma and metastatic melanoma; and are in Phase I and Phase II clinical trials for various indications, and in Phase II clinical trials for the treatment of diagnosed and recurrent glioma. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Is AGEN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 6.19
52 Week Low 1.54
Average Volume 2,054,451
200-Day Moving Average 2.5393
50-Day Moving Average 2.5128
20-Day Moving Average 2.9115
10-Day Moving Average 3.333
Average True Range 0.2716
ADX 26.71
+DI 37.003
-DI 13.6324
Chandelier Exit (Long, 3 ATRs ) 3.0652
Chandelier Exit (Short, 3 ATRs ) 2.7648
Upper Bollinger Band 3.851
Lower Bollinger Band 1.972
Percent B (%b) 0.9
BandWidth 64.53718
MACD Line 0.31
MACD Signal Line 0.2494
MACD Histogram 0.0607
Fundamentals Value
Market Cap 365.94 Million
Num Shares 99.7 Million
EPS -1.26
Price-to-Earnings (P/E) Ratio -2.91
Price-to-Sales 8.62
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.09
Resistance 3 (R3) 4.11 4.00 4.02
Resistance 2 (R2) 4.00 3.89 3.99 4.00
Resistance 1 (R1) 3.83 3.82 3.78 3.81 3.97
Pivot Point 3.72 3.72 3.69 3.71 3.72
Support 1 (S1) 3.55 3.61 3.50 3.53 3.37
Support 2 (S2) 3.44 3.54 3.43 3.34
Support 3 (S3) 3.27 3.44 3.32
Support 4 (S4) 3.25